BioNTech Results Presentation Deck
A Leading Provider of COVID-19 Vaccines Globally
Ensuring Equitable Vaccine Access to Children and Low & Lower Middle-Income Countries
U.S. exercised final purchase option under existing contract with purchase of 50 m pediatric doses
Includes vaccines for children under 5 years of age
• Brings total U.S. vaccine doses secured to 600 m
2 bn doses pledged through end of 2022 to ensure global
equitable vaccine access*
●
●
●
Plan to initiate construction of state-of-the-art mRNA vaccine
manufacturing site in Africa in mid-2022
11
Agreement with U.S. government to provide 1 bn doses for donation.
via COVAX to 100 countries, including those in African Union
Expanding manufacturing network to Africa and South America
Development and implementation of scalable regional manufacturing network in
Africa to enable an annual manufacturing capacity of several 100 m vaccine doses
As of beginning of November 2021; In combination with contract entered into by Pfizer
BIONTECHView entire presentation